EY R&D Workbench for Pharma

 

The EY R&D Workbench for Pharma is a unique tech solution for effective project planning management, workflow and issue and query tracking in the R&D environment. It leads to improved market speed and increased transparency and accountability throughout various organizations involved in formulation (across multiple dosage forms), API and biosimilar.

What EY can do for you

In the pharma sector, R&D processes are often siloed, leading to suboptimal outcomes. Roles and responsibilities are not clearly defined, leading to slow down in the growth of organization. EY R&D Workbench provides a holistic solution to transform the R&D ecosystem by providing opportunities like:

EY r d ecosystem by providing opportunities
EY r d ecosystem by providing opportunities

EY R&D Workbench has successfully resolved critical issues of the pharma sector, leading to efficient processes and tangible impact.

EY pharma 01
EY pharma 02
EY pharma 03
EY pharma 04
EY pharma 05
EY pharma 06
EY pharma 07
EY pharma 08

EY R&D Workbench is a one-stop cross-departmental collaborative platform to monitor and keep pace with the dynamically transforming R&D environment with enhanced transparency and accountability throughout the organization.

Key features:

  • Digitize portfolio management by integrating IMS data and other databases
  • Manage portfolios via customizable method upload, validation flow, molecule-level backend, dynamic exclusion based on market analysis, and representative display with confirmation/ versioning
  • Include product selection, technical evaluation, complexity assessment, commercial evaluation, and PIF as part of portfolio evaluation and product selection modules
  • Implement predictive risk assessment

  • Track R&D with project management, automated processes, predefined SLAs, and issue tracking
  • Digitize workflows, integrate with tools like SAP, LIMS, ELN
  • Use customized templates for various dosage forms and markets
  • Manage launch activities with project management, online team selection, task allocation, SLAs, and stage gate approvals
  • Digitize workflows, maintain audit trails, integrate with ERP tools
  • Utilize customizable activity templates tailored for markets and launches
  • Monitor clinical activities across teams, sites, countries, and clients
  • Utilize established workflows, stages, milestones, SLAs, and ownership for each clinical phase and dosage type.
  • Track dossier submission, deficiency management, and post-approval activities
  • Define workflows, stages, milestones, SLAs, and ownership for each market/ vertical/ type of dosage
  • Integrate with quality management and document management systems
Andrew Mosker
  • Portfolio and Project management functionality
  • Collaboration with workflows
  • Basic project management functionality
  • Re-baselining with version history and change management
  • Issue tracking
  • Timesheet module for effective utilization
  • Admin modules and user management
  • Digitized and automated notifications and escalations
  • Budget allocation and monitoring
  • Document upload
Andrew Mosker
  • Tailored reports and dashboards with features like search queries, analytics overviews, and budgeting. 
  • Detailed workflows for administrative tasks like SLA changes and approvals. 
  • Role-specific dashboards providing actionable updates and status visibility for ongoing and upcoming tasks.

Why EY

R&D has been a key focus area for most Indian pharma companies. Though India is a leader in terms of ANDA approvals globally, there is a significant scope for improving the same to achieve faster launches. We have been working with leading pharma companies to transform their R&D organizations. As a part of the transformation program, we have delivered a reduction in end-to-end timelines (Initiation to Launch) of ~15 to 20%, improving FTR (First Time Right) to >85% across R&D processes. We look at R&D from an enterprise-wide perspective, including critical elements of people, process, and technology.

The typical transformation journey kicks off by re-designing the organization structure to support the agreed to-be processes. Once the same is implemented, the processes are enabled with an EY proprietary tool called “R&D Workbench for Pharma.” It is a unique solution, led by experienced professionals with strong global experience of working in R&D technology enablement programs and change management. EY has empowered organizations with several such fit-for-purpose tech platforms and tools, boosting their end-to-end process capabilities.

Our latest thinking

How innovation is shaping India’s key sectors

Explore how innovation in India leads growth across agriculture, energy, healthcare via agritech, clean energy, telemedicine, AI and sustainable tech.

How GCCs in India are shaping the future of the Life Sciences industry

Explore how India’s GCCs are transforming future of life sciences from handling core and enabling functions to driving innovation, outcome-oriented growth.

How to expand future-ready healthcare in India

Read how India’s healthcare is going digital with AI, telemedicine, data analytics, value-based care and interoperable platforms for better access & outcomes

How Agentic AI can transform industries by 2028

Agentic AI: Transforming industries by 2028 with autonomous decision-making, improved efficiency, and ethical frameworks. Learn how it’s reshaping businesses.

Why India should focus on health and education to achieve Viksit Bharat status

Prioritizing health and education is key to harnessing India's demographic dividend. Enhanced spending on these sectors fosters growth, employment, and productivity. Learn more.

Can AI drive scalable innovation in life sciences?

AI in life sciences is transforming healthcare with advancements in R&D, personalized medicine, MedTech innovation & strategies for sustainable AI adoption.

How much productivity can GenAI unlock in India? The AIdea of India 2025

Explore AIdea of India 2025 to find out how Gen AI is transforming industries, boosting productivity & reshaping India’s digital economy with innovation.

AIdea 2025 report - Industries in transformation: Life Sciences

GenAI is reshaping India’s life sciences sector, with 32%–34% productivity gains by 2030. Explore its role in drug discovery, manufacturing, & challenges.

AIdea 2025 report - Industries in transformation: Healthcare

Explore how GenAI is revolutionizing healthcare in India, improving patient care, diagnostics, and telemedicine, with a 30%–32% productivity boost by 2030.

What will it take for India to become a global pharma powerhouse by 2047?

Explore India’s roadmap to a $450B pharma industry by 2047, powered by digital transformation, AI-driven innovation, and strategic industry collaboration.

India’s MedTech transformation: paving the path to global leadership

India's MedTech industry is undergoing a revolution. Explore the latest trends, government support, and the potential for global dominance. Learn more.

Confronting India’s cancer crisis: The urgent need for affordable care

India battles rising cancer rates. Learn about challenges, prevention, early detection, and affordable treatment options. Know more.

Transforming healthcare in India with Generative AI

Explore how GenAI can revolutionize Indian healthcare by enhancing accessibility, quality & collaboration while integrating tech with thoughtful oversight.

    Explore our case studies

    How a manufacturer eliminates cost and value leakages with AI-ML

    Discover how EY AI-enabled tool helps a roofing solutions manufacturer improve production efficiency while maintaining quality standards. Learn more about AI in manufacturing use case.

    How a young cement company grew 2.5x with organizational and functional transformation

    Learn how EY helped a young cement manufacturer grew production capacity by 2.5x facilitated by data-driven transformation.

    How a state government transformed into an ecotourism haven

    Discover how EY partnered with a state government to boost economy & create employment via sustainable ecotourism, showcasing green development in action.



      Contact us
      Like what you’ve seen? Get in touch to learn more.